Skip to main content

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference and Wet AMD & DME Drug Development Summit

Written by Customer Service on . Posted in Public Companies.

ALPHARETTA, Ga., April 05, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021:

Needham Virtual Healthcare Conference
Monday, April 12, 2021 at 12:45 p.m. ET

  • The live and archived Needham Virtual Healthcare Conference presentation webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.

Wet AMD & DME Drug Development Summit
Wednesday, April 14, 2021
Event details are available on the conference website.

  • 10:45 a.m. ET – Panel Discussion: Ending the Burden of Monthly Treatments – Mechanisms to Increasing the Durability & Accessibility of Wet AMD & DME Therapeutics
  • 1:40 p.m. ET – Suprachoroidal Drug Delivery & CLS-AX: A Potential Solution for Treatment Burden
  • 2:55 p.m. ET – Chair Led Q&A: Making Strides Forward in Drug Delivery & Dosing

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.